MedDataX Logo

Autophagy/Apoptosis Balance During Pregnancy

NCT ID: NCT04443660

Last Updated: 2025-12-31

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Total Enrollment

97 participants

Study Classification

OBSERVATIONAL

Study Start Date

2020-12-30

Study Completion Date

2025-04-07

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The object of this study is to assess the intra- and inter-individual variability of apoptosis and autophagy activities in women during pregnancy: 1 / in women with a normal pregnancy and 2 / in pregnant women particularly at risk of complications.

The study investigators hypothesize that there would be an intra-trophoblastic dialogue between the mechanisms of autophagy and apoptosis, the promotion of one partially inhibiting the other. The increase in trophoblastic autophagy during pregnancy could thus constitute an anti-apoptosis defense phenomenon, the exhaustion of which would lead to cellular apoptosis and to pathogenic consequences when it devastates the syncytiotrophoblast.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Pregnancy Related

Keywords

Explore important study keywords that can help with search, categorization, and topic discovery.

Autophagy Apoptosis

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

COHORT

Study Time Perspective

PROSPECTIVE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Group A

without medical history or risk factors, with a normal pregnancy

Blood test

Intervention Type OTHER

Blood samples taken to test levels of autophagy and apoptosis

Group B

without medical history or risk factors, developing a pregnancy complication

Blood test

Intervention Type OTHER

Blood samples taken to test levels of autophagy and apoptosis

Group C

with risk of complication, having a normal pregnancy

Blood test

Intervention Type OTHER

Blood samples taken to test levels of autophagy and apoptosis

Group D

with a risk of complication, developing a pregnancy complication

Blood test

Intervention Type OTHER

Blood samples taken to test levels of autophagy and apoptosis

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Blood test

Blood samples taken to test levels of autophagy and apoptosis

Intervention Type OTHER

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Patients followed at the CHU Nimes prior to 33 weeks gestation who give birth at the hospital
* The patient must have given their free and informed consent and signed the consent form
* The patient must be a member or beneficiary of a health insurance plan

Exclusion Criteria

* The subject is participating in a category 1 interventional study associated with a medication, or is in a period of exclusion determined by a previous study
* The subject refuses to sign the consent
* It is impossible to give the subject informed information
* The patient is under safeguard of justice or state guardianship
* Multiple pregnancy
Minimum Eligible Age

18 Years

Eligible Sex

FEMALE

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Centre Hospitalier Universitaire de Nīmes

OTHER

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Responsibility Role SPONSOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Sylvie Bouvier

Role: PRINCIPAL_INVESTIGATOR

CHU Nimes

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

CHU de Nimes

Nîmes, , France

Site Status

Countries

Review the countries where the study has at least one active or historical site.

France

References

Explore related publications, articles, or registry entries linked to this study.

Fortier M, Portes M, Demattei C, Nouvellon E, Mercier E, Bourguignon C, Chea M, Gris JC, Letouzey V, Bouvier S. Thrombin generation reference values using the ST Genesia and STG-Thromboscreen assay in pregnant women. Thromb Res. 2025 Nov 29;257:109558. doi: 10.1016/j.thromres.2025.109558. Online ahead of print. No abstract available.

Reference Type RESULT
PMID: 41371090 (View on PubMed)

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

NIMAO/2019-01/SB-01

Identifier Type: -

Identifier Source: org_study_id